Dr. Mandal is an Endowed Professor of Pharmacy. He is also Adjunct Professor at University of Tennessee College of Pharmacy at Memphis, University of Louisiana School of Pharmacy at Monroe, and Louisiana State University Health Sciences Center. He is the founding Director for the Center for Nanomedicine and Drug Delivery and Associate Director for the Louisiana Vaccine Center. He is a member of the United States Pharmacopeia (USP). Dr. Mandal has been elected as Fellow of the American Association of Pharmaceutical Scientists (AAPS). He has been recognized for his outstanding contributions in the area of novel and innovative drug delivery.
Education:
Ph.D., Pharmaceutics/Pharmacy, University of Louisiana at Monroe. 1991
Our research focuses on the design and development of commercially viable formulations to improve the safety, efficacy, and patient compliance. Cutting-edge research in our laboratory has resulted in controlled release formulations of many therapeutic agents. The microencapsulation techniques developed in our lab have resulted in effective control release formulations for large and small molecules with varying water solubility. One of our formulations has successfully completed Phase I human clinical trial. We have published close to 200 original research papers, reviews, abstracts, and monographs and filed five patents.
Patent and Intellectual Property Experience:
Issued United States Patent
K. Mandal and R. Graves. Method of microencapsulation. US Patent Number US8,628,701B2. January 14, 2014.
Patent Application Submitted (United States)
K. Mandal, D. D. Chinta, R. Graves. Controlled release multiple layer coating. US Patent (US/11-739,219).
S. Bhattacharjee and T. K. Mandal. A method of inhibiting angiogenesis. (US Patent /US/12/807,062).
Dash, T. K. Mandal, A. Kundu, and P. Chandra, S. Hazari. Delivery of siRNA via nanosomes to inhibit hepatitis C virus replication. (Provisional US Patent application/ US/ 61/519,725).
K. Mandal, N. Kumar, A. K. Kundu, A. M. Gopalakrishnan. Composition and Method for Transfection of Plasmodium falciparum. (Provisional US Patent application/ US/ 61/764,630).
Selected Publications:
G.A. Ledet, R.A. Graves, E.Y. Glotser, T.K. Mandal, and L.A. Bostanian. Preparation and In Vitro Evaluation of Hydrophilic Fenretinide Nanoparticles. Int. J. Pharm. 479 (2): 329-337 (2015).
R.A. Graves, G.A. Ledet, E.Y. Glotser, L.A. Bostanian, and T.K. Mandal. Formulation and Evaluation of Biodegradable Nanoparticles for the oral delivery of Fenretinide. Eur. J. Pharm. Sci.76: 1-9 (2015).
Kumar, G. Ledet, R. Graves, D. Datta, S. Robinson, G. P. Bansal, T. K. Mandal, (Joint Corresponding author) Kumar N. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles. Pharm. Res. [Published online: Jun 26]. (2015).
A. Ledet, S. Biswas, V. P. Kumar, R. A. Graves, D. M. Mitchner, T. M. Parker, L. A. Bostanian, S. P. Ghosh, T. K. Mandal. Development of orally administered γ-Tocotrienol (GT3) nanoemulsion for radioprotection. Int. J. Mol. Sci. Dec 24; 8(1) (2016).
Powell D, Chandra S, Dodson K, Shaheen F, Wiltz K, Ireland S, Syed M, Dash S, Wiese T, Mandal T, Kundu A. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm. May; 114:108-118. (2017).